Today: 19 May 2026
S&P Global stock price rebounds today — what SPGI investors are watching next
12 February 2026
2 mins read

S&P Global stock price rebounds today — what SPGI investors are watching next

New York, Feb 12, 2026, 14:26 EST — Regular session

  • S&P Global shares picked up in the afternoon, snapping a two-day losing streak.
  • That decision comes right after a steep selloff triggered by lower-than-expected profit guidance for 2026.
  • AI disruption jitters are on traders’ minds, but the ratings and index business remains robust.

S&P Global clawed back some ground on Thursday, with shares gaining 1.7% to close at $397.23. The stock bounced after a choppy start, trimming losses from its post-earnings slump earlier this week as buyers returned.

The stock rebounded after sliding 2.6% to $390.76 the previous day—well below the broader market, which barely moved. Volume spiked to more than twice its usual pace.

Why it matters now: S&P Global’s outlook has turned into a stress test for a segment investors long saw as rock-solid—think financial data, benchmarks, credit ratings—right as generative AI starts to challenge assumptions about how much pricing muscle these businesses can hang onto.

S&P Global posted fourth-quarter revenue of $3.916 billion on Tuesday, a 9% climb from last year. Adjusted diluted earnings per share came in at $4.30. Looking ahead, the company set its 2026 adjusted diluted EPS target between $19.40 and $19.65, with organic constant-currency revenue expected to rise 6% to 8%. CEO Martina Cheung described the “pace of AI integration” as “a leap forward.”

The company stated that adjusted results leave out items like merger costs and amortization tied to acquired intangibles. It also pointed to ongoing uncertainty regarding when the Mobility spin might happen. As for data, the plan is to release monthly billed issuance and exchange-traded derivatives figures on the 15th of each month—or the next business day—reporting one month behind.

Since the release, the stock’s behavior has echoed that of a software-and-services play, as investors largely looked past the quarter and zeroed in on S&P Global’s outlook for 2026, which calls for slower growth.

Stifel’s Shlomo Rosenbaum described the results as “mixed,” warning that the stock was “likely to be pressured.” He flagged weaker free cash flow than anticipated—cash remaining after capex—and guidance that fell short of the company’s own medium-term targets. Investing.com

S&P Global’s reach runs from credit ratings to the S&P Dow Jones indices, making it something of a bellwether for the sector. When sentiment turns against the group, traders have been quick to scan Moody’s and Nasdaq for any signs of knock-on effects.

S&P Global’s shares yo-yoed from $381.88 up to $399.49 on Thursday. Investors wasted no time punishing so-called “defensive” data and analytics stocks after guidance missed the mark.

Still, there’s risk on the table. Should AI concerns continue to weigh on sector multiples, or if a slowdown in debt issuance squeezes ratings-driven transaction income, management could soon be under pressure from investors demanding more concrete proof that both growth and margins will stay resilient into 2026.

Next up for investors: data. S&P Global is set to post its initial January numbers for billed issuance and exchange-traded derivatives around Feb. 16—since the 15th lands on a weekend. The figures could offer the first hints at what’s ahead for the ratings pipeline.

Stock Market Today

  • GF Securities Raises Nvidia Price Target to $308 Ahead of Earnings
    May 19, 2026, 10:00 AM EDT. GF Securities raised its price target on Nvidia to $308 from $292 ahead of the chipmaker's fiscal first-quarter earnings, citing Nvidia's strong cash position and potential share buybacks. Analyst Jeff Pu noted a slight shift in the Rubin platform timeline but maintained the 2300W spec. The firm expects Nvidia to grow its data-center silicon market share with products like Vera CPU and LPX, and possibly launch an inferencing-focused GPU. While fiscal 2027 earnings estimates remain steady, fiscal 2028 forecasts rose by 13% due to anticipated higher Blackwell shipments and pricing, partially offset by lower Rubin unit assumptions.

Latest articles

Bakkt Up Early After Director Buys $4.85M in Shares

Bakkt Up Early After Director Buys $4.85M in Shares

19 May 2026
Bakkt shares jumped 14.2% to $9.96 in pre-market trading Tuesday after a filing showed director Michael Alfred’s vehicle bought $4.85 million in stock. SEC documents said Alfred acquired 585,000 shares last week via Alpine Fox LP. CEO Akshay Naheta exercised options for 33,557 shares at $10 each. Bakkt recently reported Q1 revenue of $243.6 million, down sharply from a year earlier.
Relay Therapeutics Shares Rise In Pre-Market Ahead Of Key Drug Update

Relay Therapeutics Shares Rise In Pre-Market Ahead Of Key Drug Update

19 May 2026
Relay Therapeutics shares jumped 11.3% to $13.47 in premarket trading Tuesday after reporting a 60% volumetric response rate in 20 evaluable patients from its Phase 2 trial of zovegalisib for vascular anomalies. The company said 95% of patients saw some lesion reduction at 12 weeks. No patients discontinued due to adverse events. The regular Nasdaq session was set to open at 9:30 a.m. ET.

Popular

Ondas Shares Drop Following $199 Million AI Defense Deal, Traders Eye Next Steps

Ondas Shares Drop Following $199 Million AI Defense Deal, Traders Eye Next Steps

18 May 2026
Ondas Inc. shares dropped about 10% to $9.555 in midday Nasdaq trading Monday after announcing a $199 million all-stock acquisition of Israeli defense software firm Omnisys and filing for potential resale of over 2.2 million shares tied to a previous deal. Trading volume topped 48 million shares. The Omnisys deal is expected to close in Q2, pending approvals and retention of key staff.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz
Previous Story

Stock Market Today 12.02.2026

Eli Lilly stock: LLY closes at $1,040 as $1.5 billion pill stockpile comes into focus
Next Story

Eli Lilly stock: LLY closes at $1,040 as $1.5 billion pill stockpile comes into focus

Go toTop